Genprex, Inc. (GNPX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GNPX
- Company Genprex, Inc.
- Price $1.51
- Changes Percentage 260.38
- Change 1.091
- Day Low $0.51
- Day High $2.04
- Year High $14.8
- Year Low $0.28
- Market Cap $3,908,711
- Price Avg 50 EMA (D) $0.52
- Price Avg 200 EMA (D) $2.89
- Exchange NASDAQ
- Volume 275,382,428
- Average Volume 632,068
- Open $0.55
- Previous Close $0.42
- EPS -15.6
- PE -0.10
- Earnings Announcement 2024-11-12 10:59:00
- Shares Outstanding $2,588,550
Company brief: GENPREX, INC. (GNPX )
- Healthcare
- Biotechnology
- Dr. Mark S. Berger M.D.
- https://www.genprex.com
- US
- N/A
- 03-29-2018
- US3724462037
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.